Fred R Hirsch

List of Publications by Year
in descending order

156 papers	17,459 citations	38742 50 h-index	15266 126 g-index
158 all docs	158 docs citations	158 times ranked	18979 citing authors

#	Article	IF	Citations
1	Lung cancer: current therapies and new targeted treatments. Lancet, The, 2017, 389, 299-311.	13.7	2,267
2	Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology, 2003, 21, 3798-3807.	1.6	1,333
3	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. Journal of Thoracic Oncology, 2017, 12, 208-222.	1.1	1,067
4	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 853-861.e4.	16.8	725
5	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1051.	7.1	658
6	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	27.6	646
7	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	1.1	589
8	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2018, 142, 321-346.	2.5	586
9	Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6838-6845.	1.6	574
10	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. Journal of Thoracic Oncology, 2018, 13, 1248-1268.	1.1	515
11	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 763-774.	10.7	431
12	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 323-358.	1.1	408
13	New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet, The, 2016, 388, 1012-1024.	13.7	381
14	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	1.1	329
15	Increased <i>EGFR</i> Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. Journal of Clinical Oncology, 2008, 26, 3351-3357.	1.6	278
16	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. Journal of Thoracic Oncology, 2015, 10, 985-989.	1.1	241
17	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2018, 20, 129-159.	2.8	241
18	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Cancer Immunology Research, 2019, 7, 630-643.	3.4	217

#	Article	IF	Citations
19	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	1.1	212
20	Lung Master Protocol (Lung-MAP)â€"A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research, 2015, 21, 1514-1524.	7.0	205
21	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	1.1	203
22	LAG-3 Protein Expression in Nonâ€"Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	1.1	192
23	Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer, 2003, 41, 29-42.	2.0	189
24	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
25	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	1.1	182
26	TIM-3, a promising target for cancer immunotherapy. OncoTargets and Therapy, 2018, Volume 11, 7005-7009.	2.0	172
27	Lymphocyteâ€activation geneâ€3, an important immune checkpoint in cancer. Cancer Science, 2016, 107, 1193-1197.	3.9	168
28	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	1.1	156
29	Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. Oncologist, 2015, 20, 316-322.	3.7	151
30	Long non-coding RNA *UCA1* induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in *EGFR*-mutant non-small cell lung cancer. Oncotarget, 2015, 6, 23582-23593.	1.8	144
31	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clinical Cancer Research, 2014, 20, 3299-3309.	7.0	141
32	â€œInterchangeabilityâ€•of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17.	5.5	135
33	Intratumoral Heterogeneity of *ALK*-Rearranged and *ALK*/*EGFR* Coaltered Lung Adenocarcinoma. Journal of Clinical Oncology, 2015, 33, 3701-3709.	1.6	129
34	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncology, The, 2015, 16, 328-337.	10.7	124
35	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. Archives of Pathology and Laboratory Medicine, 2016, 140, 326-331.	2.5	118
36	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology, 2013, 8, 373-384.	1.1	113

#	Article	IF	Citations
37	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 110-120.	1.1	108
38	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology, 2020, 15, 29-49.	1.1	106
39	HER2/neu expression in malignant lung tumors. Seminars in Oncology, 2002, 29, 51-58.	2.2	92
40	A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. Journal of Thoracic Oncology, 2012, 7, e36-e38.	1.1	87
41	Review of Recent Advances in Fluorescence Bronchoscopy in Early Localization of Central Airway Lung Cancer. Oncologist, 2001, 6, 257-262.	3.7	83
42	MHC class II expression in lung cancer. Lung Cancer, 2017, 112, 75-80.	2.0	80
43	FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clinical Cancer Research, 2015, 21, 4356-4364.	7.0	75
44	Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342. Journal of Clinical Oncology, 2010, 28, 4747-4754.	1.6	66
45	Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Clinical Cancer Research, 2006, 12, 3652-3656.	7.0	62
46	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncology, The, 2018, 19, 101-114.	10.7	62
47	Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Current Opinion in Oncology, 2005, 17, 118-122.	2.4	60
48	The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology, 2019, 14, 1172-1183.	1.1	60
49	MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget, 2014, 5, 7902-7916.	1.8	57
50	The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Seminars in Oncology, 2004, 31, 75-82.	2.2	56
51	ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 106-111.	2.6	54
52	Early detection of lung cancer by using an autoantibody panel in Chinese population. OncoImmunology, 2018, 7, e1384108.	4.6	54
53	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. Clinical Lung Cancer, 2018, 19, e421-e430.	2.6	53
54	cMET Exon 14 Skipping: From the Structure to the Clinic. Journal of Thoracic Oncology, 2016, 11, 1423-1432.	1.1	51

#	ARTICLE	IF	CITATIONS
55	Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. Journal of Thoracic Oncology, 2017, 12, 1388-1397.	1.1	49
56	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216.	1.1	49
57	Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. Molecular Oncology, 2020, 14, 1947-1965.	4.6	48
58	Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819. Clinical Cancer Research, 2012, 18, 4004-4012.	7.0	45
59	From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. Journal of Thoracic Oncology, 2016, 11, 287-299.	1.1	45
60	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight, 2017, 2, e90449.	5.0	45
61	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 2257-2265.	4.1	41
62	A Phase II Study of Telisotuzumab Vedotin in Patients With câ€"MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical Lung Cancer, 2021, 22, 170-177.	2.6	41
63	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	1.1	40
64	KRAS G12Câ€"Mutant Nonâ€"Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2021, 23, 507-520.	2.8	40
65	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients withÂnon-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	39
66	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Translational Lung Cancer Research, 2019, 8, 352-366.	2.8	38
67	EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. Cancer Treatment Reviews, 2019, 72, 15-27.	7.7	37
68	Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prevention Research, 2016, 9, 96-104.	1.5	34
69	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal of Thoracic Oncology, 2018, 13, 205-217.	1.1	33
70	Galectin-9 in non-small cell lung cancer. Lung Cancer, 2019, 136, 80-85.	2.0	32
71	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 43-49.	2.6	31
72	EGFRâ€"TKIs plus local therapy demonstrated survival benefit than EGFRâ€"TKIs alone in EGFRâ€"mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. International Journal of Cancer, 2019, 144, 2605-2612.	5.1	30

#	ARTICLE	IF	CITATIONS
73	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. Lung Cancer, 2018, 125, 115-120.	2.0	29
74	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 895-906.	2.8	29
75	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer, 2017, 109, 1-8.	2.0	27
76	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Review of Anticancer Therapy, 2017, 17, 779-786.	2.4	27
77	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. Journal of Thoracic Oncology, 2022, 17, 214-227.	1.1	26
78	Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. Journal of Pathology, 2022, 257, 674-686.	4.5	26
79	Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. Biomarkers in Medicine, 2015, 9, 751-761.	1.4	25
80	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics, 2017, 7, 4753-4762.	10.0	25
81	sLAG-3 in non-small-cell lung cancer patients’ serum. OncoTargets and Therapy, 2018, Volume 11, 4781-4784.	2.0	25
82	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. Journal of Thoracic Oncology, 2017, 12, 27-35.	1.1	24
83	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research, 2019, 21, 72.	5.0	24
84	Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial. Lung Cancer, 2015, 88, 223-230.	2.0	23
85	Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536. Journal of Thoracic Oncology, 2013, 8, 1519-1528.	1.1	22
86	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. Journal of Thoracic Oncology, 2018, 13, 1496-1507.	1.1	22
87	c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. Lung Cancer, 2019, 133, 69-74.	2.0	22
88	Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer, 2015, 121, 2253-2261.	4.1	21
89	Clinical potential of necitumumab in non-small cell lung carcinoma. OncoTargets and Therapy, 2016, Volume 9, 5427-5437.	2.0	21
90	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). Journal of Thoracic Oncology, 2020, 15, 1748-1757.	1.1	21

#	Article	IF	Citations
91	Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer. Biology, 2021, 10, 502.	2.8	21
92	Heterogeneity in Immune Marker Expression afterÂAcquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell LungÂCancer Transformation. Journal of Thoracic Oncology, 2017, 12, 1015-1020.	1.1	20
93	Genomic Testing in Lung Cancer: Past, Present, and Future. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 323-334.	4.9	20
94	Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions. Clinical Lung Cancer, 2019, 20, e517-e530.	2.6	19
95	â€œCompanion Diagnosticsâ€: Has Their Time Come and Gone?. Clinical Cancer Research, 2014, 20, 4422-4424.	7.0	18
96	Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules. Journal of Thoracic Disease, 2018, 10, 5080-5085.	1.4	18
97	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repairâ€"Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clinical Lung Cancer, 2021, 22, 187-194.e1.	2.6	18
98	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKIâ€"Treated Patients with *EGFR*-Mutant NSCLC (SWOG S1403). Clinical Cancer Research, 2022, 28, 3752-3760.	7.0	18
99	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. Oncologist, 2021, 26, e1226-e1239.	3.7	17
100	Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Medical Science Monitor, 2016, 22, 276-283.	1.1	17
101	PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1364-1369.	1.1	16
102	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
103	Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules. OncoTargets and Therapy, 2017, Volume 10, 5915-5926.	2.0	15
104	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee â€" International Association for the Study of Lung Cancer â€" Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. Journal of Thoracic Oncology, 2019, 14, 1718-1731.	1.1	15
105	Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. Oncologist, 2022, 27, 476-486.	3.7	15
106	EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. Journal of Thoracic Oncology, 2018, 13, 228-236.	1.1	14
107	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International, 2017, 2017, 1-7.	1.9	13
108	Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. Translational Lung Cancer Research, 2019, 8, 938-950.	2.8	13

#	Article	IF	Citations
109	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	1.1	13
110	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS ONE, 2017, 12, e0172209.	2.5	13
111	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. Journal of Thoracic Oncology, 2016, 11, 1711-1717.	1.1	12
112	Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. Journal of Clinical Neuroscience, 2016, 26, 46-49.	1.5	12
113	Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer. Respiratory Research, 2019, 20, 248.	3.6	12
114	The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 1029-1038.	2.8	12
115	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clinical Lung Cancer, 2022, 23, 21-33.	2.6	12
116	Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 403-408.	3.8	11
117	EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. Lung Cancer, 2018, 120, 82-87.	2.0	11
118	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. Clinical Lung Cancer, 2019, 20, e39-e51.	2.6	11
119	Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse. Translational Lung Cancer Research, 2021, 10, 2452-2474.	2.8	11
120	Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. Cancer Cell, 2022, 40, 575-577.	16.8	11
121	First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay. Journal of Thoracic Oncology, 2008, 3, S138-S142.	1.1	10
122	Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. Seminars in Oncology, 2002, 29, 2-8.	2.2	9
123	Assessing the association of diabetes with lung cancer risk. Translational Lung Cancer Research, 2021, 10, 4200-4208.	2.8	9
124	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. Journal of Thoracic Oncology, 2019, 14, 1704-1717.	1.1	8
125	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. Journal of Thoracic Oncology, 2021, 16, 897-901.	1.1	8
126	Loss of STING expression is prognostic in non–small cell lung cancer. Journal of Surgical Oncology, 2022, 125, 1042-1052.	1.7	8

#	Article	IF	Citations
127	Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Nonâ€"Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clinical Lung Cancer, 2018, 19, 84-92.	2.6	7
128	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. Journal of Cancer, 2020, 11, 551-558.	2.5	7
129	Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2021, 156, 59-67.	2.0	7
130	Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.. Journal of Clinical Oncology, 2020, 38, 9532-9532.	1.6	7
131	Future developments in the treatment of lung cancer. Lung Cancer, 2002, 38, 81-85.	2.0	6
132	Heterogeneity in Tumors and Resistance to EGFR TKI Therapyâ€"Letter. Cancer Research, 2016, 76, 3109-3110.	0.9	6
133	Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with nonâ€'small cell lung cancer. Oncology Letters, 2019, 17, 5125-5131.	1.8	6
134	Treatment of spine metastases in cancer: a review. Journal of International Medical Research, 2020, 48, 030006051988810.	1.0	6
135	Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives. Lung Cancer, 2021, 152, 157-164.	2.0	6
136	Adjuvant TKIs in NSCLC: what can we learn from RADIANT?. Nature Reviews Clinical Oncology, 2015, 12, 689-690.	27.6	5
137	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. Clinical Lung Cancer, 2017, 18, 640-650.e2.	2.6	5
138	Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, 559-574.	2.8	5
139	EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical Lung Cancer, 2022, 23, 60-71.	2.6	5
140	CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer. Lung Cancer, 2021, 162, 194-202.	2.0	5
141	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
142	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clinical Lung Cancer, 2018, 19, 450-456.	2.6	4
143	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. Clinical Lung Cancer, 2021, , .	2.6	4
144	International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. Journal of Thoracic Oncology, 2022, , .	1.1	4

#	Article	IF	Citations
145	Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases. OncoTargets and Therapy, 2016, 9, 2409.	2.0	3
146	Physician Bias in Prophylactic Cranial Irradiation Decision Makingâ€"An Opportunity for a Patient Decision Aid. Clinical Lung Cancer, 2018, 19, 476-483.	2.6	3
147	PACIFIC trial: new perspectives for immunotherapy in lung cancer. Translational Lung Cancer Research, 2018, 7, S19-S24.	2.8	2
148	A phase 1b/2 trial of dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC.. Journal of Clinical Oncology, 2022, 40, TPS9139-TPS9139.	1.6	2
149	Longitudinal COVID-19 Vaccinationâ€"Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer. Journal of Clinical Oncology, 0, , .	1.6	2
150	Risk factors for nicotine dependence in Chinese patients with lung cancer. Journal of International Medical Research, 2019, 47, 391-397.	1.0	1
151	Programmed Cell Death Ligand 1 Expression in Resected Nonâ€"Small Cell Lung Cancer. Clinical Lung Cancer, 2020, 22, e555-e562.	2.6	1
152	Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).. Journal of Clinical Oncology, 2020, 38, 9576-9576.	1.6	1
153	EGFR expression and the flexibility of FLEX. Lancet Oncology, The, 2012, 13, 3-5.	10.7	0
154	Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses. , 2021, , .		0
155	SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).. Journal of Clinical Oncology, 2020, 38, 9623-9623.	1.6	0
156	Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. JTO Clinical and Research Reports, 2022, 3, 100269.	1.1	0